Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
IMV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.20
N/A
-1.00
vs -1.20
Q4.20
N/A
-1.10
vs -1.30
Q1.21
N/A
-1.00
vs -1.40
Q2.21
N/A
-1.10
vs -0.90
Q3.21
N/A
-1.30
vs -1.00
Q4.21
N/A
-1.40
vs -1.10
Q1.22
N/A
-1.30
vs -1.00
Q2.22
N/A
-1.20
vs -1.10
Q3.22
N/A
-1.10
vs -1.30
Q4.22
N/A
-0.99
vs -1.40
Sales Growth
YoY
Current
Estimates
Q3.20
-77%
2.2K vs 9.8K
Q4.20
-100%
111.431503 vs 25.5K
Q1.21
NA
NA vs NA
Q2.21
NA
NA vs NA
Q3.21
-100%
NA vs 2.2K
Q4.21
-100%
NA vs 111.431503
Q1.22
NA
NA vs NA
Q2.22
NA
NA vs NA
Q3.22
NA
NA vs NA
Q4.22
NA
NA vs NA
Return on Equity
QoQ
Q1.21
-27%
-0.27
vs -0.27
Q2.21
-38%
-0.38
vs -0.27
Q3.21
-32%
-0.32
vs -0.38
Q4.21
-57%
-0.57
vs -0.32
Q1.22
-93%
-0.93
vs -0.57
Q2.22
-404%
-4.04
vs -0.93
Q3.22
+118%
1.18
vs -4.04
Q4.22
+130%
1.3
vs 1.18
Institutionnal Ownership
QoQ
Q4.20
41
41
vs 39
5%
Q1.21
35
35
vs 41
-15%
Q2.21
35
35
vs 35
NA
Q3.21
32
32
vs 35
-9%
Q4.21
38
38
vs 32
19%
Q1.22
36
36
vs 38
-5%
Q2.22
37
37
vs 36
3%
Q3.22
33
33
vs 37
-11%
Quote Panel
Key Metrics
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
Relative Strenght
0
Volume Buzz
-71%
Earning Acce
Yes
Dist 52w H.
79%
businesswire.com
7 hours ago
businesswire.com
12 hours ago
businesswire.com
16 hours ago
prnewswire.com
16 hours ago
Relative Strength
IMV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|